CML-218: Primary Diagnosed CML Patient 5-Year Treatment Outcomes and Disease Incidence in an Armenian Population

Abstract

Chronic myeloid leukaemia (CML) is a highly controllable myeloproliferative disorder in the era of tyrosine kinase inhibitors (TKIs). CML incidence is 1.223:100000 and 0.967:100000 in the USA and Europe, respectively. The provided data was taken from the Armenian CML registry. We aimed to measure the outcomes of all newly diagnosed CML patients among an Armenian population during 2014–2018 and, in addition, to assess incidence of the disease. As the Haematology Centre aft. Prof. Yeolyan is the only one in Armenia, these results can be considered informative for the whole country. In this retrospective study were involved 102 CML patients (4 paediatric, 98 adult). The male/female ratio is 1.17:1. Initially, 87 patients were diagnosed in the chronic phase (CP), 9 in the accelerated phase (AP), and 6 in blast crisis (BC). High-risk patients were 16 (15.7%) by Eutos, 29 (28.4%) by Sokal, and 24 (23.5%) by Euro risk scores. Initial treatment with Imatinib was started in 100 patients. Two patients began treatment with Hydroxyurea but later switched to Imatinib. According to response, therapy was changed in 10 patients. One patient (1%) interrupted treatment for personal reasons. Fifty-two patients (51%) had a complete haematological response (CHR) in 1 month, and 86 patients (84.3%) had an CHR in 3 months. In 2–32 months, 15 patients (14.7%) had relapse. By the end of 2018, 77 patients (75.5%) had reached CR, 5 patients (4.9%) had progression of CP, 3 patients had reached AP (2.9%), 1 patient (1%) had a BC, 2 patients (2%) left the country, and 1 patient's condition of 1 patient (1%) was unknown. In 2014, 2015, 2016, 2017, and 2018, the incidence of CML was 0.7:100000, 0.6:100000, 0.8:100000, 0.4:100000, 0.9:100000, respectively. The study showed that, in Armenia, the incidence of CML is similar to European results and is increasing, and treatment outcomes tend to reach the results of developed countries. The provided data can be used by the healthcare system to manage CML in Armenia.